← Oncology Approval Tracker

FDA DECISION ·

Lunsumio

mosunetuzumab-axgb · Genentech

Accelerated approvalNew therapyFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory follicular lymphoma following at least two lines of systemic therapy.

LAMPGEN ANALYSIS

Why it matters

The original accelerated approval adds a CD20-directed bispecific in later-line follicular lymphoma.

What research teams should watch

Verify prior lines and coordinate step-up dosing, monitoring and escalation for cytokine release syndrome.

PRIMARY RECORDS

Sources